Toshi Taniguchi, MD, PhDFred Hutchinson Cancer Research Center Secondary Mutations of BRCA1/2 in BRCA 1/2 Mutated Ovarian Cancer with Primary Platinum Resistance Platinum compounds are key drugs for the treatment of ovarian cancer and often help patients gain initial remission. However, some patients do not respond, called “primary platinum resistance.” To understand why this happens, […]
Read More
Bin Zhang, MD, PhDNorthwestern University Treating ovarian cancer with novel ecto-5’nucleotidase (CD73) inhibitors Tumors have elaborate suppressive mechanisms against host immune system to enhance their survival. Ovarian tumors highly express a protein called CD73 that limits anti-tumor immune response in order to promote tumor growth. Dr. Zhang‘s recent research demonstrates that CD73 may serve as […]
Read More
Yunfei Wen, PhDUniversity of Texas MD Anderson Cancer Center Overcoming acquired resistance to antiangiogenic therapy by targeting vascular p130cas Angiogenesis, the process of forming a new network of blood vessels from existing ones, is a central hallmark of cancer. In order for a tumor to grow, it must have the blood flow necessary to feed […]
Read More
Carlos Telleria, PhDMcGill University Health Center Proteotoxic Stress Therapy in Ovarian Cancer The majority of ovarian cancers recur 18-24 months after first responding to chemotherapy. Residual cells hide out in the abdominal cavity and often become unresponsive to current chemotherapy when they grow back. Dr. Telleria researches therapies that would be administered chronically after chemotherapy […]
Read More
Wa Xian, PhDUniversity of Texas Health Science Center at HoustonHouston, TX, United States 2019 Pilot Study Award Research in Focus: Understanding and overcoming resistance to chemotherapy Resistant Cancer Stem Cell Profile in Multi-Site Metastasis of HGSC Even though ovarian cancer is typically detected very late, advances in surgery and chemotherapy have resulted in remarkable responses in […]
Read More